Ocular Evidence
Evidence database / Studies / reinstein-2021-london-evo-icl
LOW evidenceRETROSPECTIVEVerified evidence

Visual Outcomes, Footplate Position and Vault Achieved with the Visian Implantable Collamer Lens for Myopic Astigmatism

Dan Z Reinstein, Ryan S Vida, Timothy J Archer · Clinical Ophthalmology · 2021

Source
—enrolled patients*
42enrolled eyes*
1structured arms
90maximum standardized days follow-up

* Descriptive sum of reported arm counts. “≥” indicates that one or more arm counts were not reported; missing values are not treated as zero.

Study arm

EVO/EVO+ ICL

ICLEVO Implantable Collamer Lens

Population

Patients
Not reported
Eyes
42
Bilateral treatment
Not reported
Age range
Not reported
Sphere range
Not reported
Cylinder range
-4.25 to 0 D
Spherical equivalent
-16.98 to -4.4 D
Corneal thickness
Not reported

Eligibility definition

Inclusion
Consecutive EVO and EVO+ ICL procedures for myopic astigmatism sized with VHF digital ultrasound.

Exclusion
Not structured

Reported outcomes by follow-up

OutcomeFollow-upFollow-up sampleResultReported fractionProvenance
UDVA 20/20 or better
efficacy
3 months—89.0%Not reported
VERIFIED
MRSE within ±0.50 D
predictability
3 months—74.0%Not reported
VERIFIED
Refraction within ±1.00 D
efficacy
3 months—98.0%Not reported
VERIFIED
Lost at least 2 lines of CDVA
safety
3 months—0%0 / 42 eyes
VERIFIED

Complications

No structured complication observations are available for this arm. This means “not reported in this dataset,” not zero complications.